comparemela.com

Latest Breaking News On - Financial ambition statements - Page 1 : comparemela.com

AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030

Launch of 20 new medicines expected by 2030 Significant growth from existing oncology, biopharmaceuticals and rare disease portfolios Investing in disruptive innovation that will shape the future.

United-kingdom
Cambridge
Cambridgeshire
Adrian-kemp
Amolyt-pharma
Pascal-soriot
Astrazeneca
Nasdaq
Investor-relations-team
Company-secretary
Today-astrazeneca
Total-revenue

AstraZeneca Targets $80B Revenue by 2030, Growth Beyond

AstraZeneca Targets $80B Revenue by 2030, Growth Beyond
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United-kingdom
Cambridge
Cambridgeshire
Pascal-soriot
Nasdaq
Astrazeneca
Total-revenue
Chief-executive-officer
Investor-day
Financial-ambition-statements
Forward-looking-statements
Rare-diseases

AstraZeneca : BioPharmaceuticals presentation

BioPharmaceuticals Ruud Dobber, EVP and President, BioPharmaceuticals Sharon Barr, EVP, BioPharmaceuticals R&D .

Amolyt-pharma
Astrazeneca
Securities-litigation-reform-act
Financial-ambition-statements
Clinical-trials-appendix
Ambition-statements
Total-revenue

AstraZeneca sets ambition to deliver 80 billion Total Revenue by 2030 and sustained growth post 2030

Today AstraZeneca revealed its bold ambition to deliver 80 billion in Total Revenue by 2030 up from 45.8 billion in 2023.

United-kingdom
Cambridge
Cambridgeshire
Pascal-soriot
Adrian-kemp
Amolyt-pharma
Astrazeneca
Nasdaq
Investor-relations-team
Total-revenue
Chief-executive-officer
Investor-day

AstraZeneca : Rare Disease presentation - MarketScreener

Rare Disease Marc Dunoyer, CEO, Alexion and Chief Strategy Officer, AstraZeneca Gianluca Pirozzi, SVP, Head of Development and Safety, Alexion .

Amolyt-pharma
Astrazeneca
Securities-litigation-reform-act
Financial-ambition-statements
Clinical-trials-appendix
Ambition-statements
Total-revenue

vimarsana © 2020. All Rights Reserved.